The Canada Alcohol Addiction Therapeutics Market is valued at around $57 Mn in 2022 and is projected to reach $93 Mn by 2030, exhibiting a CAGR of 6.3% during the forecast period. The Increasing public awareness, government support, and advancements in research and innovation are driving the destigmatization of alcohol addiction, fostering greater acceptance of mental health, and fueling the demand for more accessible and personalized treatment options, thus increasing market growth. The key players involved in the research, development, and distribution of alcohol addiction therapeutics in Canada are AbbVie, AstraZeneca, Roche, Bausch Health, Pfizer, Otsuka, Alkermes, Ethypharm, Biovail, Beacon etc among others.
The Canada Alcohol Addiction Therapeutics Market is valued at around $57 Mn in 2022 and is projected to reach $93 Mn by 2030, exhibiting a CAGR of 6.3% during the forecast period.
Alcohol addiction, also referred to as alcoholism or alcohol use disorder (AUD), is a chronic, crippling illness marked by an individual's obsessive, uncontrolled consumption of alcohol in spite of negative outcomes. It is included in the more general group of addictive illnesses and is recognized as a drug use disorder. A mix of behavioural therapy, counselling, support groups, and medicinal interventions is frequently used in the treatment of alcohol addiction. Therapy for alcohol addiction often includes detoxification, medication-assisted therapy, counselling, and involvement in support groups such as Alcoholics Anonymous (AA). Treatment for alcohol addiction frequently involves the use of drugs such as benzodiazepines, disulfiram, naltrexone, acamprosate, topiramate, and others. Individual characteristics, such as the severity of the addiction, co-occurring mental health disorders, and general health, may influence the choice of medicine and treatment method. Comprehensive treatment strategies frequently incorporate these drugs.
Approximately 76.5% of people in the country drink alcohol, and young adults consume it at the highest rates. At least once a month, 5.1 million Canadians (15.6% of those aged 12 and over) drank heavily (5+ drinks/occasion for males, 4+ for women). Of these, almost 3.7 million Canadians who are 15 years of age or older suffer from an alcohol use problem annually. Increasing public awareness, government support, and advancements in research and innovation are driving the destigmatization of alcohol addiction, fostering greater acceptance of mental health, and fueling the demand for more accessible and personalized treatment options, thus increasing market growth.
In Canada, AbbVie Inc. is widely regarded as the dominant player in the market for prescription therapies for alcoholism. This is largely because of its primary drug, Naltrexone (sold as long-acting injectable Vivitrol), which is a first-line treatment for many individuals with alcohol dependency and is highly recommended. Also, MindBeacon, a Canadian digital mental health startup, offers the "Managing Alcohol Use" program, which is particularly developed to help those with mild to moderate alcohol problems. In the Canadian alcohol addiction therapy sector, it is regarded as an important player in the digital health segment.
Market Drivers
Increasing Awareness and Acceptance: The stigma associated with alcohol addiction is being lessened by public awareness efforts and media conversations, which is motivating people to get assistance. Acceptance of mental health is growing, which further normalizes the practice of seeking addiction treatment. Treatment-seeking behaviour can be strongly influenced by changing cultural attitudes toward alcohol and addiction, which will only serve to accelerate market growth. There is a huge demand for efficient treatment choices due to the unsettlingly large and regrettably growing patient pool.
Government Support: The Canadian government is stepping forward after realizing the urgency of the situation. Funds are being allocated by provincial and federal programs to increase treatment accessibility, including counselling, medication, and support groups. For those in need, this financial effort makes therapy more affordable and accessible.
Growing Research and Innovations: The pharmaceutical sector is always researching and creating novel drugs and alcohol addiction treatment methods. Improved recovery results are anticipated as a result of these innovative medicines, which provide patients with more individualized and effective alternatives. AI-driven platforms and solutions that evaluate patient data and forecast the likelihood of relapse are becoming more and more prevalent in the market. Tailored therapy tactics and proactive interventions are made possible by this individualized approach.
Market Restraints
Fear of Judgment: Despite increased awareness, the stigma associated with addiction endures, discouraging people from getting treatment out of concern for prejudice or judgment. This social stigma can further isolate those with addiction by obstructing help from friends and relatives.
Cost of treatment: The cost of addiction treatment, which includes counselling, medication, and support services, may be high. While certain forms of therapy, such as social support groups, are inexpensive, seeing a psychologist or therapist even once a week may get quite expensive. The primary targets, younger individuals, do not have enough money to do so. Even with insurance and government support, out-of-pocket expenses might discourage people from starting or finishing treatment.
Regulatory Obstacles: Strict regulatory procedures, protracted clinical studies, and a lack of financing for addiction research might cause a delay in the release of novel, potentially beneficial drugs.
In Canada, all hospital and physician services that are deemed medically essential are covered by the publicly financed healthcare system. To guarantee the efficacy and safety of pharmaceuticals and medical equipment, the Canadian government regulates them extensively. The Therapeutic Products Directorate (TPD) of Health Canada is the regulatory agency in charge of this function. The TPD is in charge of examining and approving medications and medical equipment for usage in Canada. Once pharmaceuticals and medical equipment are on the market, it also keeps an eye on their safety. The TPD is in charge of overseeing drug product approval and submission. The sponsoring pharmaceutical firm submits an application to Health Canada to commercialize a novel medicine in Canada. The application usually contains data on animals, chemistry, production, and the outcomes of various rounds of clinical trials. The TPD examines, certifies, and oversees the safety of pharmaceuticals and medical devices before allowing them to be used in Canada.
Key Players
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Therapy Type
By Disease Stage
By Route of Administration
By Distribution Channel
By End User
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.